PRESS RELEASE: 16 November 2021,
New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens Time
to Patient Management Decisions for Patients with Non-Small Cell
Nearly 85% of lung cancers are non-small cell lung cancers2. EGFR or ‘Epidermal Growth Factor Receptor’ mutations are the second most common cancer driver mutation in NSCLC. EGFR testing is important for the detection of EGFR mutations which helps to determine whether someone with NSCLC may benefit from targeted therapy-based regimens in case of presence of EGFR mutations, or potentially from immunotherapy-based regimens in case of absence of EGFR mutations3. EGFR mutations are commonly assessed by using Next-Generation Sequencing (NGS). This is a more complex and time-consuming technology, leading to an average expected time-to-result of approx. 15 days, which delays informed patient management decisions for patients with NSCLC.
The Idylla™ EGFR Mutation Test is a fully automated test using a slice of formalin-fixed, paraffin embedded (FFPE) tissue material as sample input, requiring less than 2 minutes hands-on-time and generating results in about 150 minutes. Previous studies4 have already reported excellent concordance between the Idylla™ EGFR Mutation Test and other routine EGFR testing methods, including NGS. This new study however specifically investigated if the faster time-to-result of the Idylla™ EGFR Mutation Test could shorten the time to patient management decisions for patients with NSCLC, as compared to NGS.
The study compared EGFR mutations analysis between the Idylla™ platform using the Idylla™ EGFR Mutation Test, and NGS in 223 patients with NSCLC. Idylla™ demonstrated 96.4% overall agreement with NGS and did not generate any false positive results5. On average, EGFR results using Idylla™ became available 12.6 calendar days earlier compared to NGS. As a result, with Idylla™, the timeframe from tumor sampling to the initiation of treatment was 16.1 calendar days earlier compared to NGS. The study concluded that the Idylla™ platform contributes to improving patient management decisions for patients with NSCLC through the faster screening of EGFR mutations.
Herman Verrelst, Chief Executive Officer of
The study can be consulted on the website of ‘Current Oncology’ here.
--- END ---
More information:
Head of
e-mail rdegrave@biocartis.com
tel +32 15 631 729
mobile +32 471 53 60 64
About
This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
1 Petiteau, C.; Robinet-Zimmermann, G.; Riot, A.; Dorbeau,M.; Richard, N.; Blanc-Fournier, C.; Bibeau, F.; Deshayes, S.; Bergot, E.; Gervais, R.; et al. Contribution of the Idylla™ System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations. Curr. Oncol. 2021, 28, 4432–4445. https://doi.org/10.3390/curroncol28060376, published
2 Hutchinson, B.; Shroff, G.S.; Truong, M.T.; Ko, J.P. Spectrum of lung adenocarcinoma.
3 Hofman, P. EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists? Cells 2021, 10, 2157. https://doi.org/ 10.3390/cells10082157, first published on
4 More info on www.biocartis.com/publications
5 The Idylla™ EGFR Mutation Test (CE-IVD) detected 20 of the 26 (77%) EGFR mutations that were detected using NGS. Regarding the seven missed EGFR mutations, five were not detected by design by the Idylla™ EGFR Mutation Test, one was assayed in a sample with insufficient neoplastic cell content for Idylla™, and the last was in a sample not validated by the Idylla™ EGFR Mutation Test (a bone metastasis)
© OMX, source